W u Yiling is a Chinese pharmaceutical billionaire whose fortune is derived from his family's stake in the traditional Chinese medicine (TCM) company, Shijiazhuang Yiling Pharmaceutical. A trained doctor of traditional Chinese medicine, he founded the company in 1992. He has built the business into a major domestic player by developing and marketing modernized versions of traditional herbal remedies.

The company's most famous and profitable product is Lianhua Qingwen, a capsule-based herbal remedy that is widely used in China for the treatment of colds and influenza. The product saw a massive and explosive surge in sales during the COVID-19 pandemic after the Chinese government officially recommended it as a treatment for the virus, despite a lack of rigorous scientific evidence for its efficacy from international clinical trials. The soaring demand for this product dramatically increased the company's revenue and stock price, turning Wu and his family, who own a controlling stake, into multi-billionaires.